,

Beximco to invest in India’s Serum Institute to produce Covid-19 vaccine

news-image

Beximco Pharmaceuticals Ltd (BPL) has announced to invest in Serum Institute of India Pvt Ltd (SII) for the development of the Covid-19 vaccine.

Beximco, fastest-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients in Bangladesh will be the exclusive distributor of SII, the largest manufacturer of vaccines in the world for this Covid-19 vaccine in Bangladesh.

The investment amount will be treated as an advance, and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis, says a press release.

Dependent on SII’s production capacity and earlier commitments to other countries, BPL’s investment amount and SII’s priority supply commitment will be determined.

BPL will also facilitate to secure the needs of the Government of Bangladesh (GOB) by offering the opportunity to reserve desired quantities for priority supply at prices to be agreed between the GOB and SII.

The Company will also secure additional quantities of the vaccine to be distributed in the private pay market in Bangladesh.

The Oxford/AstraZeneca vaccine (AZD1222) is an adenovirus vector-based vaccine, currently undergoing large scale phase III trials in Brazil, US, UK and India.

The UK trials are well underway and have shown very encouraging results and is expected to receive approval by the end of 2020. SII has already partnered with Oxford/AstraZeneca along with Gates Foundation and Gavi, to produce more than a billion doses of the vaccine for global supply.

Both Adar C Poonawalla, owner and CEO of SII and Shayan F Rahman, principal, BPL jointly commented, “We are excited to bring together two of the leading pharma companies in India and Bangladesh with the scale and capabilities to bring a vastly promising treatment to the people who need it the most.”

“This landmark agreement reflects the deep-rooted desire for collaboration between the two countries and as representatives of the two nations, between us we can go a long way towards helping to mitigate the health crisis caused by the Covid-19 pandemic,” they added.